Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 146 No. 4546 (2016)

New concepts in the management of dyslipidaemia

  • Baris Gencer
  • Nicolas Rodondi
  • Francois Mach
DOI
https://doi.org/10.4414/smw.2016.14378
Cite this as:
Swiss Med Wkly. 2016;146:w14378
Published
06.11.2016

Summary

Recently, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) published a consensus paper giving guidance on the definition and management of statin-associated muscle symptoms (SAMS), as well as the use of proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in very high-risk patients. The occurrence of SAMS can have a major negative impact on treatment adherence and, consequently, on the prognosis of cardiovascular diseases. In addition, both the ESC guidelines on the prevention of cardiovascular disease (CVD) in clinical practice with sections addressing global strategies to minimise the burden of CVD at population and individual levels, and the 2016 ESC/EAS guideline for the management of dyslipidaemias, focus on evaluation and treatment of SAMS. The release of these guidelines was a source of great interest to clinicians, as new emergent therapies, such as the PCSK9 inhibitors, have been approved for the treatment of dyslipidaemias: recently, both the US Food and Drugs Administration (FDA) and the European Medicines Agency (EMA) approved the use of PCSK9 inhibitors as add-ons for the treatment of hypercholesterolaemia in cases where low-density lipoprotein cholesterol (LDL-C) target levels could not be reached with maximum tolerated statin doses alone, or instead of statins in the event of SAMS. Because of the relatively high cost of these new therapies, physicians need to justify the use of PCSK9 inhibitors by demonstrating that their high-risk patients’ LDL-C levels have remained high (1) despite a well-conducted, but insufficiently effective high-intensity statin therapy (e.g. rosuvastatin 10–20 mg or atorvastatin 40–80 mg), or (2) in the event of the patient developing side effects, in particular severe SAMS, during treatment with at least three statins. In addition to SAMS, the use of PCSK9 inhibitors may be considered in patients with documented atherosclerotic cardiovascular disease or in patients with familial hypercholesterolaemia and poorly controlled LDL-C under the combination of maximum tolerated stain and ezetimibe.

References

  1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al.; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818. doi:http://dx.doi.org/10.1093/eurheartj/ehr158. PubMed
  2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25, Suppl 2):S1–45. doi:http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a. PubMed
  3. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al., Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405. doi:http://dx.doi.org/10.1016/S0140-6736(14)61368-4. PubMed
  4. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701. doi:http://dx.doi.org/10.1093/eurheartj/ehs092. PubMed
  5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. doi:http://dx.doi.org/10.1056/NEJMoa0807646. PubMed
  6. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34. doi:http://dx.doi.org/10.7326/0003-4819-158-7-201304020-00004. PubMed
  7. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14. doi:http://dx.doi.org/10.1007/s10557-005-5686-z. PubMed
  8. Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB, Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med. 2012;125(2):176–82. doi:http://dx.doi.org/10.1016/j.amjmed.2011.08.007. PubMed
  9. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C–60C. doi:http://dx.doi.org/10.1016/j.amjcard.2005.12.010. PubMed
  10. Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29(12):1553–68. doi:http://dx.doi.org/10.1016/j.cjca.2013.09.023. PubMed
  11. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. doi:http://dx.doi.org/10.1093/eurheartj/ehv043. PubMed
  12. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al.; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. doi:http://dx.doi.org/10.1093/eurheartj/ehw106. PubMed
  13. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al.; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 August 27. [Epub ahead of print] PubMed
  14. Gencer B, Lambert G, Mach F. PCSK9 inhibitors. Swiss Med Wkly. 2015;145:w14094. PubMed
  15. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–97. doi:http://dx.doi.org/10.1056/NEJMoa1410489. PubMed
  16. Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36):2415–24. doi:http://dx.doi.org/10.1093/eurheartj/ehv174. PubMed
  17. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al.; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi:http://dx.doi.org/10.1093/eurheartj/ehv320. PubMed
  18. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15. doi:http://dx.doi.org/10.1016/j.ahj.2014.03.019. PubMed
  19. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. doi:http://dx.doi.org/10.1161/CIRCULATIONAHA.112.136101. PubMed
  20. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102. doi:http://dx.doi.org/10.1002/path.2018. PubMed
  21. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. Can Med Assoc J. 2009;181(1–2):E11–18.
  22. Draeger A, Sanchez-Freire V, Monastyrskaya K, Hoppeler H, Mueller M, Breil F, et al. Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle. Am J Pathol. 2010;177(1):291–9. doi:http://dx.doi.org/10.2353/ajpath.2010.091140. PubMed
  23. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA; The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3, Suppl):S58–71. doi:http://dx.doi.org/10.1016/j.jacl.2014.03.004. PubMed
  24. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7. doi:http://dx.doi.org/10.1001/jama.288.4.462. PubMed
  25. Gencer B, Rodondi N, Auer R, Räber L, Klingenberg R, Nanchen D, et al. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. Eur J Intern Med. 2015;26(1):56–62. doi:http://dx.doi.org/10.1016/j.ejim.2014.12.014. PubMed
  26. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8. doi:http://dx.doi.org/10.1093/eurheartj/eht295. PubMed
  27. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74. doi:http://dx.doi.org/10.1177/2047487314525531. PubMed
  28. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–25. doi:http://dx.doi.org/10.1111/j.1472-8206.2004.00299.x. PubMed
  29. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med. 2000;160(15):2273–80. doi:http://dx.doi.org/10.1001/archinte.160.15.2273. PubMed
  30. Mannarino MR, Ministrini S, Pirro M. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med. 2014;25(7):592–9. doi:http://dx.doi.org/10.1016/j.ejim.2014.06.008. PubMed
  31. Gencer B, Laaksonen R, Buhayer A, Mach F. Use and role of monoclonal antibodies and other biologics in preventive cardiology. Swiss Med Wkly. 2015;145:w14179. PubMed
  32. Gencer B, Mach F. Sweetless’n low LDL-C targets for PCSK9 treatment. Eur Heart J. 2015;36(19):1146–8. doi:http://dx.doi.org/10.1093/eurheartj/ehv056. PubMed
  33. Santos RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet. 2015;385(9965):307–10. doi:http://dx.doi.org/10.1016/S0140-6736(14)61702-5. PubMed
  34. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors – The Clinical Benefit of Lipid Drugs. N Engl J Med. 2015;373(17):1588–91. doi:http://dx.doi.org/10.1056/NEJMp1508120. PubMed
  35. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9. doi:http://dx.doi.org/10.1056/NEJMoa1500858. PubMed
  36. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al.; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99. doi:http://dx.doi.org/10.1056/NEJMoa1501031. PubMed
  37. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):40–51. doi:http://dx.doi.org/10.7326/M14-2957. PubMed
  38. Tice JA, Kazi DS, Pearson SD. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. JAMA Intern Med. 2016;176(1):107–8. doi:http://dx.doi.org/10.1001/jamainternmed.2015.7248. PubMed
  39. Shrank WH, Barlow JF, Brennan TA. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines. JAMA. 2015;314(14):1443–4. doi:http://dx.doi.org/10.1001/jama.2015.10017. PubMed
  40. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–97. doi:http://dx.doi.org/10.1056/NEJMoa1410489. PubMed
  41. Nanchen D, Gencer B, Auer R, Räber L, Stefanini GG, Klingenberg R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J. 2015;36(36):2438–45. doi:http://dx.doi.org/10.1093/eurheartj/ehv289. PubMed
  42. Gencer B, Auer R, Nanchen D, Räber L, Klingenberg R, Carballo D, et al. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis. 2015;239(1):118–24. doi:http://dx.doi.org/10.1016/j.atherosclerosis.2014.12.049. PubMed
  43. Gencer B, Nanchen D. Identifying familial hypercholesterolemia in acute coronary syndrome. Curr Opin Lipidol. 2016;27(4):375–81. doi:http://dx.doi.org/10.1097/MOL.0000000000000311. PubMed

Most read articles by the same author(s)

1 2 > >>